Release date: 9 June 2008
Promoter – Financial Intermediary
A leading pharmaceutical company carrying out internationally reputable research and development activities.Location
Description
The project comprises the financing of expenditure under the Research and Development programmes of a major European pharmaceutical company for the development of new medical treatments in the period 2008-2011.
Objectives
The project supports the development of new medical treatments.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 450 million.
Total cost (Approximate amount)
EUR 1000 million.
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centers, etc. An EIA therefore is not required by EU Directive 97/11. To be further assessed during appraisal. Compliance of R&D activities with relevant EU legislation will also be verified during appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Status
Signed - 18/11/2008